• survival
  • This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus BEAM transplant regimen versus a regimen adding Bexxar to BEAM. (clinicaltrials.gov)
  • Therefore, the primary endpoint of this study will be to compare progression-free survival after autologous hematopoietic stem cell transplantation for chemotherapy-sensitive diffuse large B-cell lymphoma using Rituxan/BEAM versus Bexxar/BEAM for pre-transplant conditioning. (clinicaltrials.gov)
  • clinical
  • See " Immune Dysregulation and Vascular Risk in HIV-Infected Patients: Implications for Clinical Care " in volume 203 on page 439. (pubmedcentralcanada.ca)
  • The last several years have seen considerable developments in the area of HIV biomedical prevention, and the field has been reinvigorated by the results of several randomized controlled clinical trials in the area of antiretrovirals for prevention, and both systemic and topical antiretrovirals as pre-exposure prophylaxis. (lww.com)
  • preventive
  • The experience from the past 5 years highlights the importance of conducting efficacy studies that continue to move us closer toward the goal of a safe, effective, durable, and universal HIV preventive vaccine. (lww.com)
  • adults
  • The purpose of the present study was to determine whether SCD diagnosis is associated with lower rate of concurrent HIV diagnosis in Africane-American adults who are hospitalised, based on data collected in the USA. (pubmedcentralcanada.ca)
  • risk
  • Although effective HIV therapy appears to reduce the risk of CVD, it may not fully reverse HIV-associated vascular risk, and long-term exposure to HIV therapy may have direct adverse effects on CVD [ 4 ]. (pubmedcentralcanada.ca)
  • Chronic inflammation, which is a well-accepted CVD risk factor in the non-HIV setting, may also be important. (pubmedcentralcanada.ca)
  • studies
  • CD4 cell counts of 200 x 10(6)/1 or below in natural history studies and surveillance: is one enough or are two better? (ox.ac.uk)
  • Results from all efficacy studies done to date have generated new information, which has advanced the HIV vaccine field in important ways. (lww.com)
  • approaches
  • We also describe the recent advances in the search for broadly neutralizing antibodies and discuss potential approaches to circumvent the challenge posed by the enormous diversity of HIV-1. (lww.com)
  • Despite advances in elucidating the structure of broadly neutralizing antibodies (BnAbs), approaches to circumvent the great diversity of HIV, this goal is still some years away. (lww.com)
  • although
  • In surveillance programmes, however, such an approach may be impractical because of missing or infrequent serial CD4 counts, although adjustments can be made based on these estimates of premature misclassification. (ox.ac.uk)